Hystero-salpingo scintigraphy for fallopian tubal patency assessment: results from a prospective study

Author(s):  
Judit Lörincz ◽  
Salvatore Giovanni Vitale ◽  
Sándor Kristóf Barna ◽  
Fanni Dinkó ◽  
Gaetano Riemma ◽  
...  
2016 ◽  
Vol 58 (2) ◽  
pp. 307-311 ◽  
Author(s):  
Wolfgang Peter Fendler ◽  
Martin Barrio ◽  
Claudio Spick ◽  
Martin Allen-Auerbach ◽  
Valentina Ambrosini ◽  
...  

2006 ◽  
Vol 124 (5) ◽  
pp. 264-266 ◽  
Author(s):  
Julio Elito Junior ◽  
Kyung Koo Han ◽  
Luiz Camano

CONTEXT AND OBJECTIVE: As there is little information about fertility outcomes among women following clinical treatment (methotrexate and expectant management) and surgery (salpingectomy) consequent to ectopic pregnancy, we evaluate the results from hysterosalpingography subsequent to treatment. The objective was to evaluate contralateral tubal patency using hysterosalpingography following surgery and clinical treatment of tubal pregnancy. DESIGN AND SETTING: This was a prospective study at the Department of Obstetrics of Universidade Federal de São Paulo, a tertiary center. METHOD: Among 115 patients who underwent hysterosalpingography following surgery and clinical treatment of tubal pregnancy between April 1994 and February 2002, 30 were treated with a single intramuscular dose of methotrexate (50 mg/m²), 50 were followed up expectantly and 35 underwent salpingectomy. RESULTS: The patency of the ipsilateral tube was 84% after methotrexate treatment and 78% after expectant management. In addition, contralateral tubal patency was 97% after methotrexate treatment, 92% after expectant management and 83% after salpingectomy. There were no statistically significant differences between the clinical treatment and surgery groups. CONCLUSIONS: The findings from this study suggest similar contralateral tubal patency rates following salpingectomy, methotrexate treatment and expectant management.


2001 ◽  
Vol 35 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Mehmet Aktekin ◽  
Taha Karaman ◽  
Yesim Yigiter Senol ◽  
Sukru Erdem ◽  
Hakan Erengin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document